福森药业(1652.HK)连涨3日累涨24.66% 明日即将公布业绩
格隆汇3月30日丨“十四五”规划支持中医药特色创新发展,带动港股市场中药概念股集体走强。其中,福森药业(1652.HK)大涨11.52%报4.55港元,为连续第三日上涨,三个交易日已累涨24.66%,股价创今年2月17日以来新高,最新市值35亿港元。值得注意的是,公司即将于明日公布业绩,此前公司发布业绩预告称,由于市场需求增加,推动集团的主要产品双黄连口服液销售额增加,预计集团2020年股东应占溢利为人民币6300万-7500万元,同比增加约21%至44%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.